Trevena (NASDAQ:TRVN) Stock Price Crosses Above Fifty Day Moving Average – What’s Next?

Shares of Trevena, Inc. (NASDAQ:TRVNGet Free Report) passed above its 50 day moving average during trading on Monday . The stock has a 50 day moving average of $1.70 and traded as high as $1.86. Trevena shares last traded at $1.84, with a volume of 1,956 shares.

Analysts Set New Price Targets

A number of equities analysts have weighed in on TRVN shares. HC Wainwright reaffirmed a “neutral” rating and set a $5.00 target price on shares of Trevena in a research note on Thursday, November 14th. StockNews.com started coverage on shares of Trevena in a research note on Tuesday. They set a “sell” rating for the company.

Check Out Our Latest Report on TRVN

Trevena Price Performance

The stock’s 50 day simple moving average is $1.70 and its two-hundred day simple moving average is $3.35. The firm has a market cap of $1.59 million, a P/E ratio of -0.04 and a beta of 1.05.

Trevena (NASDAQ:TRVNGet Free Report) last announced its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($5.79) earnings per share for the quarter. The company had revenue of $0.28 million for the quarter. Equities research analysts anticipate that Trevena, Inc. will post -23.04 earnings per share for the current year.

Trevena Company Profile

(Get Free Report)

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.

See Also

Receive News & Ratings for Trevena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena and related companies with MarketBeat.com's FREE daily email newsletter.